Exenatide was the first glucagon like peptide-1 (GLP-1) agonist approved for treatment in patients with type 2 diabetes. Clinical trials and real-world studies of exenatide, a subcutaneous injection given twice per day, indicate that it significantly reduces hemoglobin A1c values and weight with a low risk of hypoglycemia. Exenatide is generally well tolerated, but transient nausea and vomiting are commonly occurring side effects. Given this profile, exenatide has been shown to be cost effective relative to insulin glargine. Thus, exenatide is a treatment option that should be considered for patients with type 2 diabetes that is uncontrolled on one or more oral agents and for which additional weight gain and hypoglycemia are undesirable.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Publishing in Clinical Medicine Reviews in Vascular Health was a pleasant experience. The process was fast and fair. The staff were very professional and we were well informed of the progress of the manuscript.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)